The safety profile was consistent with previous studies [6, 7] and with effects of IL-6 signaling blockade, a higher incidence of infections, elevated alanine aminotransferase (ALT) and total serum cholesterol, and decreased neutrophil count (but not associated with the occurrence of infections) with sarilumab compared with placebo. This evidence concerns the gene GPT and infection.